Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Dementia and Geriatric Cognitive Disorders

• Publication date

  2007-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1159/000105162PMID 17622761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change

  2017cited by this paper
• Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

  2006cited by this paper
• Realistic expectations for treatment success in Alzheimer's disease.

  2006cited by this paper
• Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease

  2005cited by this paper
• Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

  2005cited by this paper
• Alzheimer's disease.

  2004cited by this paper
• Disease Stage in Alzheimer Disease and Treatment Effects of Rivastigmine

  2004cited by this paper
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

  2004cited by this paper
• Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease

  2004cited by this paper
• Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• Agitation in Alzheimer’s Disease Is a Manifestation of Frontal Lobe Dysfunction

  2003cited by this paper
• Patient and caregiver characteristics and nursing home placement in patients with dementia.

  2002cited by this paper
• Diagnosis and Management of Alzheimer's Disease and Other Dementias

  2001cited by this paper
• Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?

  2001cited by this paper
• Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening.

  2000cited by this paper
• Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease

  2000cited by this paper
• Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine)

  1999cited by this paper
• Tau in Alzheimer's disease.

  1998cited by this paper
• An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease

  1997cited by this paper
• Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

  1997cited by this paper
• Behavioral complications and their treatment in Alzheimer's disease.

  1997cited by this paper
• Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.

  1997cited by this paper
• The Severe Impairment Battery: Concurrent Validity and the Assessment of Longitudinal Change in Alzheimer's Disease

  1997cited by this paper
• Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

  1997cited by this paper
• Behavioral complications and their treatment in Alzheimer's disease.

  1997cited by this paper
• Evaluating the Driving Competence of Dementia Patients

  1997cited by this paper
• A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

  1994cited by this paper
• Severe impairment battery. A neuropsychological test for severely demented patients.

  1994cited by this paper
• Factors determining the decision to institutionalize dementing individuals: a prospective study.

  1993cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper

• [Clinical guidelines «Cognitive disorders in the elderly and senile persons»].

  2025cites this paper
• Dietary Components as Promoters of Medicinal Activity in Alzheimer’s Disease

  2022cites this paper
• Expert Consensus on Cognitive Dysfunction in Diabetes

  2022cites this paper
• Effects of Dizocilpine, Midazolam and Their Co-Application on the Trimethyltin (TMT)-Induced Rat Model of Cognitive Deficit

  2021cites this paper
• The effect and pharmacology of Yizhi Sheng Hui decoction on Alzheimer's disease.

  2021influential citation
• Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients

  2021cites this paper
• Chinese Prescription Kangen-karyu as Potential Anti-Alzheimer’s Disease Therapeutic: Analyses of BACE1 and GSK-3b Inhibitory Activities

  2021cites this paper
• The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

  2021cites this paper
• Anti-dementia Medications: Specific Agents

  2020cites this paper
• Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis

  2020cites this paper
• Memantine for dementia.

  2019cites this paper
• Current and Future Treatments in Alzheimer's Disease

  2019cites this paper
• The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.

  2019cites this paper
• Memantine in Japanese patients with moderate to severe Alzheimer’s disease: meta-analysis of multiple-index responder analyses

  2018cites this paper
• Revisión de los criterios diagnósticos del deterioro cognitivo leve: nuevos marcadores predictivos de la enfermedad de Alzheimer

  2018cites this paper
• Rosmarinic Acid Derivatives’ Inhibition of Glycogen Synthase Kinase-3β Is the Pharmacological Basis of Kangen-Karyu in Alzheimer’s Disease

  2018cites this paper
• Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes

  2017cites this paper
• Activation of Two Different Drugs Used in Alzheimer’s Disease Treatment on Human Carbonic Anhydrase Isozymes I and II Activity: an In Vitro Study

  2017cites this paper
• Practical Pharmacology of Memantine

  2016cites this paper
• L’électroencéphalographie : un bio-marqueur pour le développement clinique de nouveaux traitements pharmacologiques de la maladie d’Alzheimer

  2016cites this paper
• Demographic and clinical characteristics related to cognitive decline in Alzheimer disease in China

  2016cites this paper
• Medications used in dementia: a review of evidence

  2015influential citation
• Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease

  2015cites this paper
• From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy

  2014cites this paper
• Therapeutic Class Overview Alzheimer's Agents

  2014cites this paper
• Development and validation of the Greek Severe Impairment Battery (SIB)

  2014cites this paper
• Н.А. Тювина, В.В. Балабанова Кафедра психиатрии и наркологии ГБОУ ВПО «Первый Московский медицинский государственный университет им. И.М. Сеченова» Минздрава России, Москва, Россия 119021, Москва, ул. Россолимо, д. 11, стр. 9

  2014cites this paper
• Rapid cognitive decline in Alzheimer's disease: a literature review

  2013cites this paper
• Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease

  2013cites this paper
• Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

  2013influential citation
• Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials

  2013cites this paper
• Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial

  2013cites this paper
• Effectiveness of antidementia drugs in delaying Alzheimer's disease progression

  2013cites this paper
• Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease

  2013cites this paper
• Memantine in Patients with Moderate to Severe Alzheimer's Disease: Meta-Analyses Using Realistic Definitions of Response

  2013cites this paper
• Kliniczne znaczenie blokowania receptora NMDA

  2013cites this paper
• Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections

  2012cites this paper
• Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD

  2012cites this paper
• Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.

  2012cites this paper
• [Assessment of benefits of drug therapies: memantine for Alzheimer's disease as an example].

  2012cites this paper
• Consensus 2012 sur le diagnostic et le traitement des patients atteints de démence en Suisse

  2012cites this paper
• Cost‐effectiveness of memantine in moderate and severe Alzheimer's disease in Norway

  2012cites this paper
• Management of patients with Alzheimer’s disease: pharmacological treatment and quality of life

  2012cites this paper
• A review of the effects of memantine on clinical progression in Alzheimer's disease

  2012cites this paper
• Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease

  2012cites this paper
• Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias

  2012cites this paper
• Zur Bewertung des Nutzens medikamentöser Therapieoptionen am Beispiel von Memantin bei Alzheimer Demenz

  2012cites this paper
• The contribution of N-terminally modified amyloid beta to the etiology of Alzheimer's disease

  2012cites this paper
• Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing

  2011cites this paper
• Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology

  2011cites this paper
• An Open-Label, Multicenter Observational Study for Patients with Alzheimer's Disease Treated with Memantine in the Clinical Practice

  2011cites this paper
• Protection from Glutamate-Induced Excitotoxicity by Memantine

  2011cites this paper
• Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

  2011cites this paper
• Drug treatment for people with dementia.

  2011cites this paper
• Memantine in dementia: a review of the current evidence

  2011cites this paper
• Nonmedical treatment of patients with dementia.

  2011cites this paper
• Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study

  2011cites this paper
• Drug Therapy of Post-Stroke Aphasia: A Review of Current Evidence

  2011cites this paper
• Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

  2011cites this paper
• Combination Therapy in Moderate to Severe Alzheimer’s Disease - Overview and Discussion Points for the Future

  2011cites this paper
• Development of an in vitro tool to measure the function of neurons protected from glutamate-induced excitotoxicity

  2011cites this paper
• Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

  2010cites this paper
• The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer’s Disease

  2010cites this paper
• Assessing physician attitudes and perceptions of Alzheimer's disease across Europe

  2010cites this paper
• Implications of the impact survey for payors across Europe

  2010cites this paper
• Investigational Medications for Treatment of Patients With Alzheimer Disease

  2010cites this paper
• Agitation in Patients with Dementia - Challenges in Diagnosis and Treatment

  2010cites this paper
• Update on the use of memantine in Alzheimer's disease.

  2009cites this paper
• Review: Therapy for Alzheimer's disease: how effective are current treatments?

  2009cites this paper
• Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease

  2009cites this paper
• Memantine and constraint‐induced aphasia therapy in chronic poststroke aphasia

  2009cites this paper
• Efficacy and safety of memantine in Lewy body dementia.

  2009cites this paper
• Efficacy and safety of memantine in Lewy body dementia

  2009cites this paper
• Memantine Prevents Sensitivity to Excitotoxic Cell Death of Rat Cortical Neurons Expressing Human Truncated Tau Protein

  2009cites this paper
• Update on the use of memantine in Alzheimer’s disease

  2009cites this paper
• Memantine

  2009cites this paper
• Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias

  2009cites this paper
• Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post‐hoc analyses of ADAS‐cog and SIB total and single‐item scores from six randomized, double‐blind, placebo‐controlled studies

  2009cites this paper
• Pharmacological Treatment of Alzheimer’s Disease: Is it Progressing Adequately?

  2009cites this paper
• Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease

  2008cites this paper
• Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer's Disease

  2008cites this paper
• Galantamine in Alzheimer's

  2008cites this paper
• Galantamine in Alzheimer’s disease

  2008cites this paper
• Rapid cognitive decline in Alzheimer's disease. Consensus paper

  2008cites this paper
• [Efficacy and safety of memantine in dementia with Lewy bodies].

  2008cites this paper
• [Efficacy of memantine in Parkinson's disease with dementia].

  2008cites this paper
• Current awareness in human psychopharmacology

  2008cites this paper
• Clinical Experience of Memantine in Alzheimer’s Disease

  2008cites this paper
• Memantine for dementia.

  2006cites this paper
• Cholinesterases from plant tissues. VI. Preliminary characterization of enzymes from Solanum melongena L. and Zea mays L.

  1975cites this paper
• Clinical Interventions in Aging Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Memantine: a Review of Studies into Its Safety and Efficacy in Treating Alzheimer's Disease and Other Dementias

  year unknowncites this paper
• What is dementia ?

  year unknowncites this paper